May 22, 2018

     Program

Recorded Program

Keynote Speakers

Neuronal Diversity and Co-transmission
Marisela Morales, M.S., Ph.D., Director, Core Facilities; Branch Chief, Integrative Neuroscience Branch; Section Chief; Neuronal Networks Section, NIH/NIDA

NIH Funding, Initiatives, and Resources
Changhai Cui, Ph.D., Program Director, Division of Neuroscience and Behavior, NIH/NIAAA

Alcohol and Lipid Traffic Don't Mix
Carol Casey, Ph.D., Professor of Medicine and Biochemistry, University of Nebraska Medical Center; Research Career Scientist, Omaha VAMC

 

December 13, 2017

     Program

Unraveling the National Opioid Crisis:From Biology to Better Therapies for Pain

"Opioids and Chronic Pain: Current Status and Future Directions”
Mehmet Sofuoglu, MD, PhD, Professor of Psychiatry, Yale University; Director of V.A. New England Mental Illness Research, Education, and Clinical Center

“Therapeutic Potential of Opioid and Cannabinoid Interactions”
Bernard Le Foll, MD, PhD,Professor of Pharmacology and Toxicology, Head of Translational Addiction Research Laboratory, & Head of Alcohol Research and Treatment Clinic, University of Toronto

 

May 24, 2017

     Program

Keynote Speakers:

Craig McClain, M.D., Professor of Medicine, Pharmacology & Toxicology, University of Louisville School of Medicine; Chief GI, Robley Rex VAMC, Louisville, KY

Philippe de Timary, M.D., Ph.D.,Professor of Psychiatry & Neuroscience, Catholic University of Louvain and Hospital Saint-Luc, Brussels, Belgium

 

December 14, 2016

     Program

Cannabis and its medicinal potential: State of the research and policy

 

May 27, 2016

     Program

Keynote Speakers:

Antonello Bonci, MD, Scientific Director, NIDA/NIH

Lorenzo Leggio, MD, PhD,Clinical Investigator, NIAAA DICBR and NIDA IRP Chief, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIAAA DICBR and NIDA IRP
Associate Director for Clinical Research, Medication Development Program, NIDA IRP

 

Dec 11, 2015​

     Program

Keynote Address:

Drug Design for Addiction - Translating the Atypical Dopamine Uptake Inhibitor Hypothesis
Amy Newman, PhD, Deputy Scientific Director, Chief of Molecular Targets & Medications Discovery Branch, Chief of Medicinal Chemistry Section, NIDA/NIH

 

Preclinical Models of Alcohol Dependence: What can they tell us about Medications?
Mark Egli, PhD, Program Officer, Division of Neuroscience & Behavior, NIAAA/NIH

 

May 22, 2015

     Program

Keynote Address:

Impaired Endocannabinoid Signaling in Stress and Addiction
Larry Parsons, Ph.D., Committee on the Neurobiology of Addictive Disorders, NIAAA Alcohol Research Center at TSRI, Pearson Center for Alcoholism and Addiction Research, The Scripps Research Institute, La Jolla, CA

 

Dec 12, 2014​

​     Program

Keynote Address:

Alcohol, HIV, and Physiologic Frailty in the 21st Century
Amy Justice, M.D., Ph.D., Professor of Medicine and of Public Health, Section Chief of General Internal Medicine, VA Connecticut Healthcare System, Yale University

 

May 23, 2014

     Program

Keynote Address:

The Vulnerable Brain: Pathway to Addiction Disorder
Yasmin Hurd, Ph.D., Professor of Psychiatry, Neuroscience and Pharmacology & Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York

Dec 13, 2013​

​     Program

Keynote Address:

Neuronal ensembles in addiction
Bruce T. Hope, Ph.D., Investigator National Institute of Drug Abuse (NIDA) Intramural Research Program Neurobiology of Relapse Section

 

May  31, 2013 


     Program -

                        Keynote Address:

Neuroscience & Behavioral Research at NIAAA: Research Priorities and Future Directions
Antonio Noronha, Ph.D., Director of the Division of Neuroscience and Behavior, NIAAA

     Pictures